UK markets open in 5 hours 34 minutes
NIKKEI 225
38,346.71 +144.34 (+0.38%) HANG SENG
18,313.86 0.00 (0.00%) CRUDE OIL
79.22 +0.23 (+0.29%) GOLD FUTURES
2,316.50 -5.80 (-0.25%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,216.93 -843.31 (-1.68%)
Bristol-Myers Squibb Co (BRM.MU)
Munich - Munich Delayed price. Currency in EUR
Add to watchlist
At close: 08:42PM CEST
| Previous close | 40.81 |
| Open | 40.82 |
| Bid | 40.59 x 0 |
| Ask | 40.71 x 0 |
| Day's range | 40.67 - 40.82 |
| 52-week range | 40.62 - 63.00 |
| Volume | |
| Avg. volume | 62 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
PRINCETON, N.J., May 07, 2024--Bristol Myers Squibb to Participate in Upcoming Investor Conferences
- Business Wire
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
PRINCETON, N.J., May 06, 2024--U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
- Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
PRINCETON, N.J., May 06, 2024--European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line....
© 2024 Yahoo. All rights reserved.